Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
antibody
cancer
immunotherapy
ovarian cancer
pancreatic cancer
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
10 05 2022
10 05 2022
Historique:
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
10
5
2022
Statut:
ppublish
Résumé
SignificanceMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical development.
Identifiants
pubmed: 35512094
doi: 10.1073/pnas.2202439119
pmc: PMC9171807
doi:
Substances chimiques
Antibodies, Monoclonal
0
GPI-Linked Proteins
0
Receptors, Chimeric Antigen
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2202439119Subventions
Organisme : NIGMS NIH HHS
ID : R24 GM137782
Pays : United States
Organisme : HHS | National Institutes of Health (NIH)
ID : S10OD018530
Organisme : HHS | National Institutes of Health (NIH)
ID : R24GM137782
Références
Mol Cancer Res. 2020 Feb;18(2):229-239
pubmed: 31676721
Sci Transl Med. 2013 Oct 23;5(208):208ra147
pubmed: 24154601
Mol Cancer Ther. 2016 Jul;15(7):1648-55
pubmed: 27196771
MAbs. 2017 Apr;9(3):567-577
pubmed: 28353419
Mol Ther. 2018 Apr 4;26(4):963-975
pubmed: 29503199
Expert Opin Biol Ther. 2021 Apr;21(4):473-486
pubmed: 33176519
Anticancer Res. 2012 Dec;32(12):5151-8
pubmed: 23225411
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Clin Cancer Res. 2021 Mar 1;27(5):1452-1462
pubmed: 33262134
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17099-104
pubmed: 17940013
Sci Rep. 2015 May 21;5:9928
pubmed: 25996440
Cancer Res. 2011 Sep 1;71(17):5915-22
pubmed: 21775520
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Commun Biol. 2020 Dec 1;3(1):728
pubmed: 33262421
Cell Death Dis. 2019 Jun 17;10(7):476
pubmed: 31209210
J Biol Chem. 2009 Feb 6;284(6):3739-49
pubmed: 19075018
Gastroenterology. 2018 Jul;155(1):29-32
pubmed: 29567081
Cancer Discov. 2021 Nov;11(11):2748-2763
pubmed: 34266984
Clin Cancer Res. 2005 Aug 15;11(16):5840-6
pubmed: 16115924
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
pubmed: 19211796
J Immunol. 2017 May 15;198(10):3999-4011
pubmed: 28404636
Cancer Cell. 2017 Mar 13;31(3):383-395
pubmed: 28262555
Cancer Discov. 2016 Feb;6(2):133-46
pubmed: 26503962
Blood. 2013 Feb 14;121(7):1165-74
pubmed: 23243285
Clin Cancer Res. 2010 Dec 15;16(24):6132-8
pubmed: 21037025
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
J Biol Chem. 2012 Sep 28;287(40):33123-31
pubmed: 22787150
MAbs. 2020 Jan-Dec;12(1):1739408
pubmed: 32191151
Cell Rep Med. 2021 Jun 01;2(6):100297
pubmed: 34195677
Genome Res. 1999 Aug;9(8):677-9
pubmed: 10447503
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439085
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319